Patients with liver disease. Use of the drug in patients with liver disease has not been studied.
The drug should be taken for exemestane a long time, while continuing to follow a diet that is adhered to the patient prior to treatment Traykorom 160 mg.
> 1/1000, <1/100: Venous thromboembolism exemestane (pulmonary embolism, deep vein thrombosis).
From the circulatory and lymphatic system:
> 1/10000, <1/1000: increased the concentration of hemoglobin and white blood cells.
From the nervous system:
> 1/10000, <1/1000: sexual dysfunction, headache.
From the respiratory system:
<1/10000: interstitial pneumopathy.
Skin and subcutaneous tissue:
> 1/1000, <1/100: rash, pruritus, urticaria or exemestane photosensitivity reactions.
> 1/10000, <1/1000: alopecia.
<1/10000: photosensitivity, accompanied by erythema , blistering or nodules on the skin areas exposed to sunlight or artificial UV light (e.g., quartz tubes), in some cases (even after many months of use without any complications).
> 1/1000, <1/100: increased creatinine and urea in serum.
Cases of overdose have not been described. A specific antidote is not known. If you suspect an overdose, symptomatic and should be appointed, if necessary, supportive care. Hemodialysis is ineffective.
Interaction with other drugs
Fenofibrate enhances oral anticoagulant effect and may increase the risk of bleeding, which is associated with the displacement of the anticoagulant binding sites to plasma proteins.
At the beginning of the treatment with fenofibrate it is recommended to reduce the dose of anticoagulants by about a third, followed by gradual dose selection. Selection of doses recommended controlled level (international normalized ratio).
described several severe cases of reversible decrease in renal function during simultaneous treatment with fenofibrate and cyclosporin. It is therefore necessary to monitor the status of renal function in these patients, and to cancel the fenofibrate in the event of a serious change in laboratory parameters.
HMG-CoA reductase inhibitors and other fibrates
When receiving fenofibrate together with inhibitors of Hexemestane reductase inhibitors or other fibrates increases the risk of serious toxic effects on muscle fibers .
Cytochrome P450 Enzymes: Studies in vitro microsomes from human liver have shown that fenofibrate and fenofibric acid are not inhibitors of the following cytochrome isoenzymes . At therapeutic concentrations of these compounds are weak inhibitors weak or moderate inhibitors .